In addition, in patients with acute myelocytic leukemia, the overexpression of IGF2BP2 indicates poor survival, and IGF2BP2 expression is associated with mutations in FLT3-ITD and IDH1, which are also indicators of poor prognosis [46]. Here, IGF2BP2 is linked to acute myeloid leukemia.